Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstratin...

Authors:Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu and Yuhua Li

Citation:Biomarker Research 2020 8:18

Content type:Review

 

Published on: 27 May 2020

• ViewFull Text
 
• ViewPDF